American Family Children's Hospital
Douglas G. McNeel, MD, PhD close
Douglas G. McNeel, MD, PhD

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Douglas G. McNeel, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. McNeel is a genitourinary medical oncologist with a clinical and research focus on prostate cancer immunology. Since 1997 he and his laboratory have studied vaccines for prostate cancer, specifically identifying antigens to target in vaccines, testing the ability of vaccines to eliminate prostate cancer cells and translating these studies to human clinical trials.


Medical Oncology

UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital (primary)
Veterans Hospital - Wm. S. Middleton Memorial (secondary)

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship University of Washington School of Medicine, Seattle
Fred Hutchinson Cancer Research Center
Residency University of Washington School of Medicine, Seattle
Internship University of Washington School of Medicine, Seattle
Medical School University of Chicago, Pritzker School of Medicine, Chicago, IL, 1994


Best Doctors® in America 2015

Best Doctors® in America 2014

Best Doctors® in America 2013


Languages Spoken

English, French
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
Heninger E Krueger TE Thiede SM Sperger JM Byers BL Kircher MR Kosoff D Yang B Jarrard DF McNeel DG Lang JM . Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget. 2016 Oct 17;
[PubMed ID: 27769045]
Ehlerding EB England CG McNeel DG Cai W . Molecular Imaging of Immunotherapy Targets in Cancer. J Nucl Med. 2016 Oct;57(10):1487-1492
[PubMed ID: 27469363]
Colluru VT McNeel DG . B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Oncotarget. 2016 Sep 21;
[PubMed ID: 27661128]
Rekoske BT McNeel DG . Immunotherapy for prostate cancer: False promises or true hope? Cancer. 2016 Sep 20;
[PubMed ID: 27649312]
England CG Ehlerding EB Hernandez R Rekoske BT Graves SA Sun H Liu G McNeel DG Barnhart TE Cai W . Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-labeled Pembrolizumab. J Nucl Med. 2016 Aug 4;
[PubMed ID: 27493273]
Bloom JE McNeel DG . SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget. 2016 Jun 2;
[PubMed ID: 27276714]
Choueiri TK Fishman M Escudier B McDermott DF Drake CG Kluger HM Stadler WM Perez-Gracia JL McNeel DG Curti BD Harrison MR Plimack ER Appleman L Fong L Albiges L Cohen LJ Young TC Chasalow SD Ross-MacDonald P Srivastava S Jure-Kunkel M Kurland JF Simon JS Sznol M . Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 May 11;
[PubMed ID: 27169994]
Colluru VT Johnson LE Olson BM McNeel DG . Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol. 2016 Apr;34(4):193-204
[PubMed ID: 24332642]
Rekoske BT Olson BM McNeel DG . Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology. 2016 Mar 28;5(6):e1165377
[PubMed ID: 27471641]
Rekoske BT Smith HA Olson BM Maricque BB McNeel DG . PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res. 2015 Aug;3(8):946-55
[PubMed ID: 26041735]
McNeel DG Chen YH Gulley JL Dwyer AJ Madan RA Carducci MA DiPaola RS . Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother. 2015;11(10):2469-74
[PubMed ID: 26111351]
McNeel DG Gardner TA Higano CS Kantoff PW Small EJ Wener MH Sims RB DeVries T Sheikh NA Dreicer R . A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014 Oct;2(10):988-99
[PubMed ID: 25189164]
McNeel DG Becker JT Eickhoff JC Johnson LE Bradley E Pohlkamp I Staab MJ Liu G Wilding G Olson BM . Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res. 2014 Jul 15;20(14):3692-704
[PubMed ID: 24850844]
Smith HA Rekoske BT McNeel DG . DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine. 2014 Mar 26;32(15):1707-15
[PubMed ID: 24492013]
Lang JM Wallace M Becker JT Eickhoff JC Buehring B Binkley N Staab MJ Wilding G Liu G Malkovsky M McNeel DG . A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer. 2013 Dec;11(4):407-15
[PubMed ID: 23835291]
Casavant BP Mosher R Warrick JW Maccoux LJ Berry SM Becker JT Chen V Lang JM McNeel DG Beebe DJ . A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods. 2013 Dec 1;64(2):137-43
[PubMed ID: 23806645]
Becker JT McNeel DG . Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination. J Immunother Cancer. 2013 May 29;1:2
[PubMed ID: 24764533]
Olson BM McNeel DG . Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol. 2013 May 6;3:109
[PubMed ID: 23653893]
Cetnar J Wilding G McNeel D LoConte NK McFarland TA Eickhoff J Liu G . A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May;31(4):436-41
[PubMed ID: 21481618]
Olson BM Johnson LE McNeel DG . The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother. 2013 Mar;62(3):585-96
[PubMed ID: 23108626]